Intravitreal corticosteroid approved

Article

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris 80 mg/mL has been indicated for sympathetic ophthalmia, temporal arteritis, uveitis and other conditions unresponsive to treatment with topical corticosteroids.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Related Content
A woman stands at a lectern delivering a presentation to an audience. She is viewed through the blur of the crowded audience. Image credit: ©as-artmedia – stock.adobe.com

Industry preview: Eye care companies announce presentations ahead of ASRS meeting

Sydney M Crago
July 16th 2024
Article

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An architectural impression of the Oriel eye health centre exterior. Rendering courtesy Moorfields Eye Charity.

Impact report highlights outcomes of Moorfields Eye Charity programmes

Hattie Hayes
July 12th 2024
Article

The organisation has secured £72.75 million for its new eye health centre

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A 2mg branded Ozempic injector. Image credit: ©Fernanda – stock.adobe.com

Semaglutide may be associated with non-arteritic ischemic optic neuropathy (NAION)

Lynda Charters
July 9th 2024
Article

GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific

A scientist in a laboratory puts samples into a petri dish. Image credit: ©RFBSIP – stock.adobe.com

Beacon Therapeutics announces new board members, funding to support XLRP and AMD programmes

Martin David Harp
July 8th 2024
Article

The company has secured $170 million (approximately €157 million) in Series B funding

© 2024 MJH Life Sciences

All rights reserved.